Gergely Tóth, PhD, MBA is the CEO, CSO and founder of Cantabio Pharmaceuticals, a biopharmaceutical company focusing on developing novel disease modifying precision therapeutics and diagnostics for neurodegenerative diseases. Dr. Tóth is also an Honorary Associate Professor at the School of Pharmacy at University College London, where he lectures about the business of biotech. Dr. Tóth previously held various research roles in innovative biotech and global biopharmaceutical companies in the U.S. and was later a Wellcome Trust funded research fellow at the University of Cambridge. Dr. Tóth has over 20 years of experience in the research of therapeutics and diagnostics for Alzheimer’s, and Parkinson’s disease. His research and publications were highlighted in articles by Biocentury Innovations, Scientific American and the World Economic Forum (Top 10 Emerging Technologies 2019).
Gergely Tóth
